A new prognostic model for predicting 30-day mortality in acute oncology patients

References

• Mort D, Lansdown M, Smith N, et al. For better or worse? A review of the care of patients who died within 30 days of receiving systemic anti-cancer therapy. National Confidential Enquiry into Patient Outcome and Death. UK: London; 2008.
   Google Scholar
• McPhail S, Elliss-Brookes L, Shelton J, et al. Emergency presentation of cancer and short-term mortality. Br J Cancer. 2013;109(8):2027–2034.
   PubMed Web of Science ®Google Scholar
• National Chemotherapy Advisory Group. Chemotherapy Services in England: ensuring quality and safety. 2009. [cited 2020 Sep 28]. Available from: https://webarchive.nationalarchives.gov.uk/20130104173757/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/DH_104500
   Google Scholar
• Gupta D, Lis C. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9(1):1.
   PubMedGoogle Scholar
• Templeton A, McNamara M, Šeruga B, et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: a Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2014;106(6):6.
   Google Scholar
• O’Neill T, Benepal T, Young AM, et al. Predictive markers of survival in acute oncology patients seen in a large tertiary academic hospital: neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio and CRP. NCRI Cancer Conference. Glasgow, November 2018 [ Abstract].
   Google Scholar
• Rubin D. Multiple imputation for nonresponse in surveys. John Wiley & Sons; 2004, New York.
   Google Scholar
• Harrell F, Lee K, Califf R, et al. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984;3(2):143–152.
   PubMed Web of Science ®Google Scholar
• Moons K, Altman D, Reitsma J, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (tripod): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–W73.
   PubMed Web of Science ®Google Scholar
• Steyerberg EW. Validation in prediction research: the waste by data splitting. J Clin Epidemiol. 2018;103:131–133.
   PubMed Web of Science ®Google Scholar
• Sauerbrei W, Royston P. Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. J R Stat Soc Series A. 1999;162(1):71–94.
   Google Scholar
• Royston P, Altman DG. Regression Using Fractional Polynomials of Continuous Covariates: parsimonious Parametric Modelling. J R Stat Soc. 1994;43(3):429–467.
   Google Scholar
• Royston PA. G. sg81: multivariable fractional polynomials.Stata Technical Bulletin 1998;43:24–32.
   Google Scholar
• Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. 2006. [2006 November 14]. published Online First: Med Decis Making. 26(6):565–574.
   PubMed Web of Science ®Google Scholar
• Wood AM, Royston P, White IR. The estimation and use of predictions for the assessment of model performance using large samples with multiply imputed data. Biom J. 2015 January 29;57(4):614–632. published Online First.
   PubMed Web of Science ®Google Scholar
• Van Houwelingen JC, Le Cessie S. Predictive value of statistical models. Stat Med. 1990;9(11):1303–1325.
   PubMed Web of Science ®Google Scholar
• Royston P, Parmar MK, Sylvester R. Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. 2004. [2004/March/18]]. published Online First: Stat Med. 23(6):907–926.
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Harrell FE. Prediction models need appropriate internal, internal–external, and external validation. J Clin Epidemiol. 2016;69:245–247.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. Cancer registration statistics, England: 2017; [cited 2021 Mar]. Available from:www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2017.
   Google Scholar
• Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104(4):726–734.
   PubMed Web of Science ®Google Scholar
• Bailey S, Bull D, Harpole D, et al. Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg. 2003;75(1):217–222.
   PubMed Web of Science ®Google Scholar
• Longo W, Virgo K, Johnson F, et al. Risk factors for morbidity and mortality after colectomy for colon cancer. Dis Colon Rectum. 2000;43(1):83–91.
   PubMed Web of Science ®Google Scholar
• Jiang W, Ma T, Zhang C, et al. Identification of urinary candidate biomarkers of cisplatin-induced nephrotoxicity in patients with carcinoma. J Proteomics. 2020;210:103533.
   PubMed Web of Science ®Google Scholar
• Kunutsor S, Apekey T, Seddoh D, et al. Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):187–201.
   PubMed Web of Science ®Google Scholar
• Keshaviah A, Dellapasqua S, Rotmensz N, et al. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol. 2006;18(4):701–708.
   Web of Science ®Google Scholar
• Oñate-Ocaña L, Aiello-Crocifoglio V, Gallardo-Rincón D, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007;14(2):381–389.
   PubMed Web of Science ®Google Scholar
• Lyons O, Whelan B, Bennett K, et al. Serum albumin as an outcome predictor in hospital emergency medical admissions. Eur J Intern Med. 2010;21(1):17–20.
   PubMed Web of Science ®Google Scholar
• Pant S, Martin L, Geyer S, et al. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine based therapy with or without bevacizumab. Cancer. 2014;120(12):1780–1786.
   PubMedGoogle Scholar
• Schernberg A, Moureau-Zabotto L, Del Campo E. Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation. Oncotarget. 2017;8(7):11579–11588.
   PubMedGoogle Scholar
• Wilcox R. Cancer-associated myeloproliferation: old association, new therapeutic target. Mayo Clin Proc. 2010;85(7):656–663.
   PubMed Web of Science ®Google Scholar
• Heng D, Xie W, Regan M, et al. Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: results from a large multicenter study. J Clin Onc. 2009;27(15_suppl):5041.
   Web of Science ®Google Scholar
• Petersen J, Stuiver M, Timmermans A, et al. Development and external validation of a risk-prediction model to predict 5-year overall survival in advanced larynx cancer. Laryngoscope. 2017;128(5):1140–1145.
   PubMed Web of Science ®Google Scholar